Unanswered questions in acute myeloid leukaemia.
Acute myeloid leukaemia (AML) is a heterogeneous disease that presents with a range of morphological, cytogenetic, immunophenotypic, and biomolecular features. Over the past 20 years, application of new cytogenetic and molecular techniques has greatly improved knowledge of the pathophysiology of AML, resulting in new potential therapeutic applications. However, the results of current therapy are still unsatisfactory, especially in patients who have adverse prognostic factors at the time of diagnosis. Furthermore, some pivotal questions about the procedures of induction and postinduction therapy of AML remain unanswered, and substantial controversy exists on the optimum therapeutic approach for the disorder.
Ferrara
Felicetto
F
Division of Haematology and Stem Cell Transplantation Unit, Cardarelli General Hospital, Naples, Italy. felicettoferrara@katamail.com
D000208:Acute Disease; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006801:Humans; D007951:Leukemia, Myeloid / Q000503:physiopathology* / Q000628:therapy*; D008875:Middle Aged; D012074:Remission Induction; D033581:Stem Cell Transplantation / Q000379:methods*; D016896:Treatment Outcome
D000970:Antineoplastic Agents